Impact of variant reclassification in the clinical setting of cardiovascular genetics
- PMID: 33029862
- DOI: 10.1002/jgc4.1336
Impact of variant reclassification in the clinical setting of cardiovascular genetics
Abstract
Genetic testing for cardiovascular disease (CVD) has advanced over the past ten years, but these advancements have posed new challenges in variant classification. To address these challenges, ACMG/AMP published guidelines for variant interpretation in 2015. This study aimed to determine what impact these guidelines have on variant classification in clinical cardiovascular genetics. A retrospective chart review identified patients who underwent clinical genetic testing and had a variant identified in a gene associated with CVD. For each variant, systematic evidence review was performed and ACMG guidelines were applied for classification. These classifications were compared to those provided on patients' genetic test reports. This study identified 223 unique variants in 237 patients. Seventy-nine (35%) of the variants had classifications that differed from their clinical reports. Twenty-eight (35%) of these reclassifications would have changed medical management recommendations for 38 patients. Application of these guidelines resulted in reclassification for approximately one-third of the variants in this study. Clinicians can have a more active role in the process of variant classification. Variant classifications should be updated over time in the clinical CVD setting due to the impact reclassifications can have on clinical screening recommendations.
Keywords: cardiovascular; genetic testing; guidelines; variant classification; variant interpretation.
© 2020 National Society of Genetic Counselors.
References
REFERENCES
-
- Ackerman, M. J. (2015). Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain/unknown significance issue. Heart Rhythm: the Official Journal of the Heart Rhythm Society, 12(11), 2325-2331. https://doi.org/10.1016/j.hrthm.2015.07.2002
-
- Amendola, L. M., Jarvik, G. P., Leo, M. C., McLaughlin, H. M., Akkari, Y., Amaral, M. D., … Rehm, H. L. (2016). Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium. American Journal of Human Genetics, 98(6), 1067-1076. https://doi.org/10.1016/j.ajhg.2016.03.024
-
- Balmaña, J., Digiovanni, L., Gaddam, P., Walsh, M. F., Joseph, V., Stadler, Z. K., … Domchek, S. M. (2016). Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. Journal of Clinical Oncology, 34(34), 4071-4078. https://doi.org/10.1200/JCO.2016.68.4316
-
- Biesecker, L., & Harrison, S. M. (2018). The ACMG/AMP reputable source criteria for the interpretation of sequence variants. Genetics in Medicine, 20(12), 1687-1688. https://doi.org/10.1038/gim.2018.42
-
- Bland, A., Harrington, E. A., Dunn, K., Pariani, M., Platt, J., Grove, M., & Caleshu, C. (2018). Clinically impactful differences in variant interpretation between clinicians and testing laboratories: A single-center experience. Genetics in Medicine, 20(3), 369-373. https://doi.org/10.1038/gim.2017.212
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
